Mycoplasma: Unique Bacterial Pathogens Without Cell Walls

In the world of microorganisms, mycoplasma stand out as truly unique pathogens. These tiny bacteria challenge our traditional understanding of what bacterial cells should look like. Unlike every other bacterium you’ll encounter in microbiology, mycoplasma completely lack the rigid cell wall that typically defines bacterial structure. This single characteristic makes them remarkably different in how they look, how they behave, and how we treat the infections they cause.

What makes mycoplasma different from other bacteria 🔗

Mycoplasma belong to a special class of bacteria called Mollicutes, which literally means “soft skin.” This name perfectly describes their defining feature: the complete absence of peptidoglycan cell walls. Instead of the tough, protective shell that surrounds most bacterial cells, mycoplasma are bounded only by a triple-layered cell membrane.

This lack of a cell wall has profound implications. First, it makes mycoplasma naturally resistant to many common antibiotics like penicillins and cephalosporins, which work by targeting cell wall synthesis. When these antibiotics are used against infections, they’re completely ineffective against mycoplasma because there’s simply no cell wall to attack.

Second, without a rigid cell wall to maintain their shape, mycoplasma cells are highly pleomorphic. They can appear as spheres, filaments, or even flask-shaped structures depending on their environment. This shape-shifting ability helps them squeeze through filters that would normally trap bacteria, which is why they were once mistakenly thought to be viruses.

Size and structure 🔗

Mycoplasma are among the smallest self-replicating organisms known to science, measuring just 0.2 to 0.3 micrometers in diameter. To put this in perspective, they’re only slightly larger than some viruses. Their membrane contains an unusual component for bacteria: cholesterol and other sterols, which they must obtain from their environment since they cannot synthesize these molecules themselves.

How mycoplasma differ from viruses 🔗

At first glance, mycoplasma might seem similar to viruses. They’re tiny, they can pass through bacterial filters, and they were historically confused with viral agents. However, there are critical differences that firmly place them in the bacterial kingdom.

The most important distinction is that mycoplasma contain both DNA and RNA, while viruses contain only one type of nucleic acid. Mycoplasma possess a complete set of cellular machinery including ribosomes, a circular chromosome, and metabolic enzymes. This allows them to reproduce independently on specially formulated cell-free media, unlike viruses which absolutely require living host cells to replicate.

Their genome, though extremely small compared to other bacteria, is still significantly larger than viral genomes. The smallest mycoplasma genome belongs to Mycoplasma genitalium at about 580 kilobase pairs, containing roughly 500 genes. While this is only about one-sixth the size of an E. coli genome, it’s still complex enough to support independent life.

Diseases caused by mycoplasma 🔗

Several mycoplasma species cause disease in humans, with Mycoplasma pneumoniae being the most clinically significant.

Atypical pneumonia (walking pneumonia) 🔗

M. pneumoniae is one of the most common causes of community-acquired pneumonia, particularly in young adults and school-aged children. The infection it causes is called atypical pneumonia or “walking pneumonia” because it differs significantly from typical bacterial pneumonia.

Unlike the sudden, severe onset of pneumococcal pneumonia, mycoplasma infections develop gradually over several days. Patients often experience mild symptoms including persistent dry cough, headache, fever, and fatigue. The cough can be particularly troublesome, often worsening at night and lasting for weeks. Many patients feel well enough to continue their daily activities despite being infected, hence the term “walking pneumonia.”

The infection spreads through respiratory droplets when infected individuals cough or sneeze. It’s particularly common in crowded settings like schools, college dormitories, and military barracks. Studies show that approximately 10-40% of community-acquired pneumonia cases are caused by M. pneumoniae.

Extrapulmonary manifestations 🔗

While respiratory symptoms are most common, M. pneumoniae can affect other body systems. These bacteria can cause skin rashes, neurological complications including encephalitis, cardiac problems, joint inflammation, and hemolytic anemia. In some cases, patients develop severe complications like Stevens-Johnson syndrome or Guillain-Barré syndrome, though these are rare.

Genitourinary infections 🔗

Other mycoplasma species colonize the genitourinary tract. Mycoplasma genitalium has emerged as a significant cause of non-gonococcal urethritis in men and has been linked to pelvic inflammatory disease in women. Mycoplasma hominis and Ureaplasma species can cause urinary tract infections, bacterial vaginosis, and complications during pregnancy including preterm birth and neonatal infections.

Why mycoplasma are difficult to cultivate 🔗

Growing mycoplasma in the laboratory presents unique challenges that explain why they were discovered relatively late in the history of microbiology and why diagnosis often relies on molecular methods rather than culture.

Complex nutritional requirements 🔗

Because of their extremely reduced genomes, mycoplasma have lost many metabolic pathways and cannot synthesize essential nutrients. They lack genes for amino acid biosynthesis, fatty acid production, and nucleotide synthesis. This means they’re completely dependent on external sources for these building blocks.

Culture media for mycoplasma must be enriched with serum (usually horse serum) to provide cholesterol and fatty acids for membrane synthesis. They also require nucleic acid precursors, specific amino acids, and various growth factors. Even with these nutrients, mycoplasma grow very slowly compared to other bacteria.

Special growth conditions 🔗

Mycoplasma colonies on agar plates are tiny, typically only 0.1 to 0.6 millimeters in diameter, and display a characteristic “fried egg” appearance with a dense center and translucent periphery. These minute colonies can be easily overlooked or mistaken for debris. Growth can take 7 to 21 days, much longer than the overnight growth typical of most pathogenic bacteria.

Some mycoplasma species, particularly M. genitalium, are so fastidious that they’re nearly impossible to culture routinely in clinical laboratories. This has led to increased reliance on molecular detection methods like polymerase chain reaction (PCR) for diagnosis.

Clinical implications and treatment 🔗

The unique biology of mycoplasma has important implications for healthcare. Since they lack cell walls, antibiotics that target cell wall synthesis are completely ineffective. Beta-lactam antibiotics including penicillins, cephalosporins, and carbapenems simply won’t work.

Effective treatment requires antibiotics that target other bacterial structures. Macrolides like azithromycin and clarithromycin are first-line treatments for M. pneumoniae infections. Tetracyclines such as doxycycline are also effective, particularly for genitourinary mycoplasma infections. Fluoroquinolones represent another treatment option, especially for severe cases or when macrolide resistance is suspected.

Unfortunately, macrolide resistance in M. pneumoniae has been increasing in some regions, complicating treatment decisions. When patients don’t respond to first-line therapy, switching to a different antibiotic class becomes necessary.

Diagnosis in modern healthcare 🔗

Given the cultivation challenges, modern diagnosis of mycoplasma infections increasingly relies on molecular methods. PCR assays can detect mycoplasma DNA directly from respiratory or genital specimens, providing results much faster than culture. Serological tests that detect antibodies against mycoplasma antigens are also commonly used, though they may not be positive early in infection.

For M. pneumoniae specifically, the cold agglutinin test, which detects antibodies that cause red blood cells to clump at cold temperatures, can provide supportive evidence of infection, though it’s not specific to mycoplasma and is positive in only about half of cases.

What do you think? Given that mycoplasma can evade many conventional antibiotics and are challenging to diagnose, how might healthcare providers improve early detection and treatment of these infections? As antibiotic resistance continues to emerge, what alternative strategies could be developed to manage mycoplasma infections more effectively?

References

1. https://bio.libretexts.org/Bookshelves/Microbiology/Microbiology_(Boundless)/04:_Cell_Structure_of_Bacteria_Archaea_and_Eukaryotes/4.04:_Cell_Walls_of_Prokaryotes/4.4D:_Mycoplasmas_and_Other_Cell-Wall-Deficient_Bacteria
2. https://www.ncbi.nlm.nih.gov/books/NBK536927/
3. https://accessmedicine.mhmedical.com/Content.aspx?bookId=2268&sectionId=176087921
4. https://www.cdc.gov/mycoplasma/hcp/clinical-overview/?CDC_AAref_Val=https://www.cdc.gov/pneumonia/atypical/mycoplasma/hcp/disease-specifics.html
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2893430/
6. https://www.ncbi.nlm.nih.gov/books/NBK7637/
7. https://www.ncbi.nlm.nih.gov/books/NBK430780/